Clinical Trial Update: A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SAGE-217 (zuranolone) for prevention of relapse in adults with major depressive disorder was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SAGE-217 (zuranolone)

Snippet

Sponsor: Biogen | Conditions: Major Depressive Disorder | Phase 3 | Status: TERMINATED | Results posted: 2022-10-03